Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | CTSK | P43235 | 4/20 | 0.49 |
| ▸ | CTSS | P25774 | 2/20 | 0.49 |
| ▸ | CTSB | P07858 | 1/20 | 0.49 |
| ▸ | AAK1 | Q2M2I8 | 7/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3038444 | 1.00 | ALDH1A1 (0.51) | ALDH1A1CTSKCTSSCTSBAAK1 | |
| SCHEMBL12020767 | 1.00 | ALDH1A1 (0.51) | ALDH1A1CTSKCTSSCTSBAAK1 | |
| SCHEMBL30554382 | 1.00 | ALDH1A1 (0.51) | ALDH1A1CTSKCTSSCTSBAAK1 | |
| SCHEMBL5849869 | 1.00 | ALDH1A1 (0.51) | ALDH1A1CTSKCTSSCTSBAAK1 | |
| SCHEMBL30083281 | 0.94 | ALDH1A1 (0.46) | ALDH1A1CTSKCTSSCTSBAAK1 | |
| SCHEMBL6227427 | 0.85 | ALDH1A1 (0.56) | ALDH1A1L3MBTL1POLB | |
| SCHEMBL30695643 | 0.85 | CTSS (0.47) | ALDH1A1CTSKCTSSCTSBAAK1 | |
| SCHEMBL19479409 | 0.84 | CTSK (0.47) | ALDH1A1CTSKCTSSPOLB | |
| SCHEMBL6487442 | 0.84 | CTSK (0.47) | CTSKCTSS | |
| SCHEMBL781623 | 0.84 | CTSK (0.47) | CTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4262788-B1 | UREA OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2026-01-21 | — | — | EP | disclosed |
| EP-4567035-A1 | NOVEL COMPOUND AS HYPOXIA-INDUCIBLE FACTOR 1(HIF-1) INHIBITOR OR VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Nextgen Bioscience Co., Ltd. (KR) | 2025-06-11 | — | — | EP | disclosed |
| US-20240383852-A1 | ANTI-VIRAL COMPOUNDS | Infex Therapeutics Limited (GB) | 2024-11-21 | — | — | US | disclosed |
| US-20240327354-A1 | GRAM-NEGATIVE BACTERIA EFFLUX PUMP INHIBITORS | INSTITUT PASTEUR DE LILLE (FR) | 2024-10-03 | — | — | US | disclosed |
| WO-2024030000-A1 | NOVEL COMPOUND AS HYPOXIA-INDUCIBLE FACTOR 1(HIF-1) INHIBITOR OR VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 주식회사 넥스트젠바이오사이언스 | 2024-02-08 | — | — | WO | disclosed |
| WO-2024030000-A1 | NOVEL COMPOUND AS HYPOXIA-INDUCIBLE FACTOR 1(HIF-1) INHIBITOR OR VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 주식회사 넥스트젠바이오사이언스 | 2024-02-08 | — | — | WO | disclosed |
| EP-4305022-A1 | ANTI-VIRAL COMPOUNDS | Infex Therapeutics Limited (GB) | 2024-01-17 | — | — | EP | disclosed |
| CN-117396462-A | Antiviral compounds | 英菲克斯治疗有限公司 | 2024-01-12 | — | — | CN | disclosed |
| EP-4262788-A1 | UREA OREXIN RECEPTOR AGONISTS | Merck Sharp & Dohme LLC (US) | 2023-10-25 | — | — | EP | disclosed |
| WO-2023064493-A1 | COMPOUNDS AND METHODS FOR TREATING CORONAVIRUSES | Clear Creek Bio, Inc. (US) | 2023-04-20 | — | — | WO | disclosed |
| WO-2013151923-A1 | PYRIMIDINONE CARBOXAMIDES AS INHIBITORS OF ENDOTHELIAL LIPASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-10-10 | — | — | WO | disclosed |
| US-8513184-B2 | Macrocyclic inhibitors of flaviviridae viruses | GILEAD SCIENCES, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-8513184-B2 | Macrocyclic inhibitors of flaviviridae viruses | GILEAD SCIENCES, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-8513184-B2 | Macrocyclic inhibitors of flaviviridae viruses | GILEAD SCIENCES, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| WO-2013048942-A1 | QUINOLINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-04 | — | — | WO | disclosed |
| US-20130022573-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | SELCIA LIMITED (GB) | 2013-01-24 | — | — | US | disclosed |
| US-20130022573-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | SELCIA LIMITED (GB) | 2013-01-24 | — | — | US | disclosed |
| US-20130022573-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | SELCIA LIMITED (GB) | 2013-01-24 | — | — | US | disclosed |
| WO-2012078915-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. (US) | 2012-06-14 | — | — | WO | disclosed |
| WO-2012078915-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. (US) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240327354-A1 | GRAM-NEGATIVE BACTERIA EFFLUX PUMP INHIBITORS | ABCB11, ABCB1, ATP4B | ALDH1A1 4679/4885CTSK 1358/4885CTSS 1250/4885 |
| US-20240383852-A1 | ANTI-VIRAL COMPOUNDS | PREP, DNPEP, PLP2 | ALDH1A1 3785/4885CTSK 156/4885CTSS 72/4885 |
| US-20130022573-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | HAVCR2, ZC3HAV1, CYP2F1 | ALDH1A1 967/4885CTSK 1746/4885CTSS 1066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.